scholarly journals Timing and Outcomes of Intracranial Stenting in the Post-SAMMPRIS Era: A Systematic Review

2021 ◽  
Vol 12 ◽  
Author(s):  
Yanying Yu ◽  
Tao Wang ◽  
Kun Yang ◽  
Xiao Zhang ◽  
Simon Chun Ho Yu ◽  
...  
Keyword(s):  
Cohort Studies ◽  
Randomized Controlled Trials ◽  
Prospective Cohort ◽  
Death Rate ◽  
Controlled Trials ◽  
Intracranial Stenting ◽  
Safety And Efficacy ◽  
Prospective Cohort Studies ◽  
Randomized Controlled ◽  
The Impact

Objective: To investigate the impact of timing on the safety and efficacy of stenting for ICAS, we reviewed high-volume randomized controlled trials or prospective cohort studies of stenting for intracranial atherosclerotic artery stenosis (ICAS) after the SAMMPRIS trial.Methods: We included randomized controlled trials or prospective cohort studies since 2011 (the publication of the SAMMPRIS trial), evaluating the outcomes of intracranial stenting for ICAS patients. The primary outcomes were perioperative and 1-year stroke or death rate. The interaction of timing and outcomes were shown on trend plots. Overall meta-analysis and subgroup analysis by timing of intracranial stenting were conducted.Results: Fourteen studies with a total of 1,950 patients were included. The perioperative and post-operative stroke or death rates decreased with the time of stenting to the qualifying events. The perioperative stroke rate was significantly higher in patients treated within 21 days after the qualifying events, compared to those beyond 21 days (IRR = 1.60, 95%CI: 1.10–2.33; p = 0.014), similar relationships were obtained for both post-procedural (IRR = 1.61, 95%CI: 1.02–2.55; p = 0.042) and 1-year (IRR = 1.51, 95%CI: 1.10–2.08; p = 0.012) stroke or death rate.Conclusions: The timing of intracranial stenting may influence the safety and efficacy outcomes of stenting. Intracranial stenting within 21 days from the qualifying events may confer a higher risk of stroke or death. More studies are needed to confirm the impact of timing and the proper cut-off value.

scholarly journals Quality Assessment of Prospective Cohort Studies Evaluating Arthroscopic Treatment for Femoroacetabular Impingement Syndrome: A Systematic Review

2019 ◽  
Vol 7 (5) ◽  
pp. 232596711983853 ◽  
Author(s):  
Axel Öhlin ◽  
Louise Karlsson ◽  
Eric Hamrin Senorski ◽  
Páll Jónasson ◽  
Mattias Ahldén ◽  
...  
Keyword(s):  
Cohort Studies ◽  
Randomized Controlled Trials ◽  
Prospective Cohort ◽  
Methodological Quality ◽  
Arthroscopic Surgery ◽  
Controlled Trials ◽  
Prospective Cohort Studies ◽  
Randomized Controlled ◽  
The Mean

Background: Femoroacetabular impingement (FAI) syndrome is a cause of pain and reduced range of motion in the hip joint. Given the limited number of randomized controlled trials, prospective cohort studies constitute the dominant part of the available prospective evidence evaluating relevant clinical outcomes after arthroscopic hip surgery for FAI. Purpose: To assess the methodological quality of prospective cohort studies evaluating arthroscopic surgery for FAI and to determine whether there has been an improvement in methodological quality over time. Study Design: Systematic review; Level of evidence, 4. Methods: A systematic literature search was performed in PubMed, Embase (OvidSP), and the Cochrane Library. Included studies were clinical prospective cohort studies of primary arthroscopic surgery for cam and/or pincer morphology FAI. Methodological quality was assessed with the Methodological Index for Non-randomized Studies (MINORS). The mean MINORS score for studies published during the first 5 years of the period was compared with those published during the last 5 years to evaluate methodological improvement over time. The methodological quality of randomized controlled trials was also assessed with the Coleman Methodology Score. Results: The search yielded 53 studies. There were 34 noncomparative studies, 15 nonrandomized comparative studies, and 4 randomized controlled trials. The included studies were published between 2008 and 2017. The mean ± SD MINORS score for noncomparative and comparative studies was 10.4 ± 1.4 of 16 possible and 18.7 ± 2.0 of 24 possible, respectively. The mean Coleman Methodology Score for randomized controlled trials was 79.0 ± 7.0 of 100 possible. Conclusion: The methodological quality of prospective cohort studies evaluating arthroscopic surgery for FAI is moderate for comparative and noncomparative studies. Common areas for improvement include unbiased assessment of study endpoints and prospective sample-size calculations. Despite an increase in the number of published studies, an improvement in methodological quality over time was not observed.

scholarly journals Calcium intake and hip fracture risk in men and women: a meta-analysis of prospective cohort studies and randomized controlled trials

2007 ◽  
Vol 86 (6) ◽  
pp. 1780-1790 ◽  
Author(s):  
Heike A Bischoff-Ferrari ◽  
Bess Dawson-Hughes ◽  
John A Baron ◽  
Peter Burckhardt ◽  
Ruifeng Li ◽  
...  
Keyword(s):  
Hip Fracture ◽  
Cohort Studies ◽  
Fracture Risk ◽  
Calcium Intake ◽  
Prospective Cohort ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Men And Women ◽  
Prospective Cohort Studies ◽  
Randomized Controlled

scholarly journals Anthocyanins, Anthocyanin-Rich Berries, and Cardiovascular Risks: Systematic Review and Meta-Analysis of 44 Randomized Controlled Trials and 15 Prospective Cohort Studies

2021 ◽  
Vol 8 ◽  
Author(s):  
Lin Xu ◽  
Zezhong Tian ◽  
Hong Chen ◽  
Yimin Zhao ◽  
Yan Yang
Keyword(s):  
Systematic Review ◽  
Cohort Studies ◽  
Prospective Cohort ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Cardiovascular Risks ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Prospective Cohort Studies ◽  
Randomized Controlled

Objective: The associations between intake of anthocyanins and anthocyanin-rich berries and cardiovascular risks remained to be established. We aimed to quantitatively summarize the effects of purified anthocyanins and anthocyanin-rich berries on major surrogate markers of cardiovascular diseases (CVDs) and the longitudinal associations between dietary anthocyanins and CVD events.Methods: Meta-analysis of randomized controlled trials (RCTs) and prospective cohort studies.Results: We included 44 eligible RCTs and 15 prospective cohort studies in this study. Pooled analysis of RCTs showed that purified anthocyanin supplementation could significantly reduce blood LDL cholesterol (weighted mean difference (WMD): −5.43 mg/dL, 95% CI: −8.96, −1.90 mg/dL; p = 0.003) and triglyceride (WMD: −6.18 mg/dL, 95% CI: −11.67, −0.69 mg/dL; p = 0.027) while increase HDL cholesterol (WMD: 11.49 mg/dL, 95% CI: 7.43, 15.55 mg/dL; p < 0.001) concentrations. Purified anthocyanins also markedly decreased circulating tumor necrosis factor alpha (WMD: −1.62 pg/mL, 95% CI: −2.76, −0.48 pg/mL; p = 0.005) and C-reactive protein (WMD: −0.028 mg/dL, 95% CI: −0.050, −0.005 mg/dL; p = 0.014). Besides, administration of anthocyanin-rich berries could significantly lower blood total cholesterol (WMD: −4.48 mg/dL, 95% CI: −8.94, −0.02 mg/dL; p = 0.049) and C-reactive protein (WMD: −0.046 mg/dL, 95% CI: −0.070, −0.022 mg/dL; p < 0.001). Neither purified anthocyanins nor anthocyanin-rich berries could cause any substantial improvements in BMI, blood pressure, or flow-mediated dilation. In addition, meta-analysis of prospective cohort studies suggested that high dietary anthocyanins were related to lower risk of coronary heart disease (CHD) (relative risk (RR): 0.83, 95% CI: 0.72, 0.95; p = 0.009), total CVD incidence (RR: 0.73, 95% CI: 0.55, 0.97; p = 0.030), and total CVD deaths (RR: 0.91, 95% CI: 0.87, 0.96; p < 0.001).Conclusion: Habitual intake of anthocyanins and anthocyanin-rich berries could protect against CVDs possibly via improving blood lipid profiles and decreasing circulating proinflammatory cytokines.Systematic Review Registration:https://www.crd.york.ac.uk/PROSPERO, identifier: CRD42020208782.

Sign in / Sign up

Export Citation Format

Share Document